However, although DA and DA-Ag have important advantages over monoclonal antibodies and TKIs in that they are economically more accessible, have greater availability, and probably have fewer adverse effects, large human studies are needed to clearly determine the full spectrum of the safety, dosing, and efficacy of using DA-related therapy as a new treatment in cancer, endometriosis, and OA. This evidence concerns the gene RENBP and cancer.